Novel 3-Aza-Bicyclo[3.3.0]octane Compounds as ERK5 Inhibitors for Treating Cancer

Provided herein are novel 3-aza-bicyclo[3.3.0]octanecompounds as ERK5 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Authors

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2026-05-27
DOI
https://doi.org/10.1021/acsmedchemlett.6c00248
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel 3-Aza-Bicyclo[3.3.0]octane Compounds as ERK5 Inhibitors for Treating Cancer

Ram W. Sabnis
ACS Medicinal Chemistry Letters
Melanoma and MAPK Pathways
article

Novel 3-Aza-Bicyclo[3.3.0]octane Compounds as ERK5 Inhibitors for Treating Cancer

Ram W. Sabnis
article en

Abstract

Provided herein are novel 3-aza-bicyclo[3.3.0]octanecompounds as ERK5 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

ACS Medicinal Chemistry Letters
Good health and well-being
Openalex Percentile: Top 9%
Melanoma and MAPK Pathways
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.